Increased Placental sFLT1 (Soluble fms-Like Tyrosine Kinase Receptor-1) Drives the Antiangiogenic Profile of Maternal Serum Preceding Preeclampsia but Not Fetal Growth Restriction.
Ovid Technologies (Wolters Kluwer Health)
MetadataShow full item record
Gaccioli, F., Sovio, U., Gong, S., Cook, E., Charnock-Jones, D. S., & Smith, G. C. (2023). Increased Placental sFLT1 (Soluble fms-Like Tyrosine Kinase Receptor-1) Drives the Antiangiogenic Profile of Maternal Serum Preceding Preeclampsia but Not Fetal Growth Restriction.. Hypertension https://doi.org/10.1161/HYPERTENSIONAHA.122.19482
BACKGROUND: Preeclampsia and fetal growth restriction (FGR) are both associated with an increased ratio of sFLT1 (soluble fms-like tyrosine kinase-1) to PlGF (placenta growth factor) in maternal serum. In preeclampsia, it is assumed that increased placental release of sFLT1 results in PlGF being bound and inactivated. However, direct evidence for this model is incomplete, and it is unclear whether the same applies in FGR. METHODS: We conducted a prospective cohort study where we followed 4212 women having first pregnancies from their dating ultrasound, obtained blood samples serially through the pregnancy, and performed systematic sampling of the placenta after delivery. The aim of the present study was to determine the relationship between protein levels of sFLT1 and PlGF in maternal serum measured at ≈36 weeks and placental tissue lysates obtained after term delivery in 82 women with preeclampsia, 50 women with FGR, and 132 controls. RESULTS: The sFLT1:PlGF ratio was increased in both preeclampsia and FGR in both the placenta and maternal serum. However, in preeclampsia, the maternal serum ratio of sFLT1:PlGF was strongly associated with placental sFLT1 level (r=0.45; P<0.0001) but not placental PlGF level (r=-0.17; P=0.16). In contrast, in FGR, the maternal serum ratio of sFLT1:PlGF was strongly associated with placental PlGF level (r=-0.35; P=0.02) but not sFLT1 level (r=0.04; P=0.81). CONCLUSIONS: We conclude that the elevated sFLT1:PlGF ratio is primarily driven by increased placental sFLT1 in preeclampsia, whereas in FGR, it is primarily driven by decreased placental PlGF.
cohort studies, fetal growth retardation, placenta, placenta growth factor, preeclampsia, Pregnancy, Female, Humans, Pre-Eclampsia, Prospective Studies, Vascular Endothelial Growth Factor Receptor-1, Placenta Growth Factor, Vascular Endothelial Growth Factor A, Receptor Protein-Tyrosine Kinases, Biomarkers
The work was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (Women’s Health theme), and grants from the Medical Research Council (United Kingdom; MR/K021133/1), and supported by the NIHR Cambridge Clinical Research Facility.
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Medical Research Council (MR/K021133/1)
External DOI: https://doi.org/10.1161/HYPERTENSIONAHA.122.19482
This record's URL: https://www.repository.cam.ac.uk/handle/1810/338135
All Rights Reserved
Licence URL: http://www.rioxx.net/licenses/all-rights-reserved
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: firstname.lastname@example.org